thought leadership rare disease genetic testing protocol design

What the FDA's new potency guidance means for rare disease gene therapy trials

Gene Therapy Vials in Biotech Lab

On November 2, 2026, the FDA issued its final guidance, Potency Assurance for Cellular and Gene Therapy Products, outlining a risk-based approach to ensuring that cell and gene therapies consistently achieve their intended biological activity. A Federal Register notice of availability followed.For rare disease gene therapy developers, the guidance has particular significance. Small patient populations and limited manufacturing lots can make it difficult to establish how product characteristics relate to clinical outcomes. When a handful of lots and trial participants form the foundation of an approval application, gaps in either manufacturing or clinical evidence can be difficult to address later.

The guidance focuses on manufacturing quality and potency testing. It also reinforces a broader development challenge: sponsors need to plan how they will generate reliable manufacturing and clinical evidence from the earliest stages of a program.

What the FDA's new potency guidance recommends

The final guidance replaces FDA's January 2011 Potency Tests guidance and finalizes a draft issued in December 2023. As described in FDA's announcement, it outlines a lifecycle approach to potency assurance for cell and gene therapy (CGT) products regulated as biologics under section 351 of the Public Health Service Act.

Rather than relying solely on a final lot-release test, FDA recommends a risk-based Potency Assurance Strategy built around five elements:

  1. Manufacturing process design: Establishing processes capable of consistently producing a product with the intended biological activity.
  2. Process control: Monitoring manufacturing parameters that may influence potency.
  3. Material control: Managing the quality of materials used in manufacturing.
  4. In-process testing: Evaluating relevant product attributes during production.
  5. Potency lot-release assays: Testing each lot against established potency criteria.

The guidance describes different approaches for short shelf-life therapies, patient-specific products manufactured using viral vectors, and directly administered viral vector products.

FDA's expectations evolve throughout development. At the IND stage, sponsors should identify preliminary critical quality attributes, assess potency-related risks, and describe the product's mechanism of action (MoA).

By significant-risk and effectiveness studies, FDA recommends at least one qualified release assay that quantitatively measures a potency-related attribute and can reject sub-potent lots. Inadequate potency assurance may result in a clinical hold.

Before submitting a biologics license application (BLA), sponsors should reassess their strategy using accumulated manufacturing, quality, and clinical data, validate release assays, and establish appropriate manufacturing controls and acceptance criteria.

Although the Federal Register notice emphasizes that guidance recommendations are non-binding, statutory potency testing requirements still apply. As DLA Piper's analysis explains, the overall framework remains consistent with the draft, while providing additional practical detail on managing potency throughout development.

Why small rare disease trials make potency assurance more challenging

One of the guidance's most consequential recommendations concerns the relationship between manufacturing consistency and clinical evidence.

FDA recommends that potency acceptance criteria for licensed products help ensure that commercial lots remain consistent with those administered during pivotal clinical studies. This means sponsors must establish meaningful connections between the product characteristics measured during development and the specifications used for commercial production.

For rare disease therapies, those connections can be difficult to demonstrate.

Small patient populations and relatively few manufacturing lots may limit opportunities to evaluate variability or establish relationships between product attributes and clinical outcomes. The guidance also cautions that statistical correlations do not necessarily establish causation. Additional mechanistic evidence may be needed to demonstrate why a particular attribute is relevant to potency.

FDA's separate guidance on human gene therapy for rare diseases recognizes the challenges of generating clinical evidence in small populations.

Together, these documents reinforce the importance of early planning. Sponsors need to consider how manufacturing controls, potency testing, and clinical data will support the evidence required at pivotal development milestones and beyond.

Why patient characterization matters to clinical evidence

Reliable manufacturing data are essential, but interpreting treatment outcomes also depends on understanding the patients who received the therapy.

In rare disease trials, where individual participants may account for a meaningful proportion of the available clinical evidence, differences in genetic diagnosis, disease progression, or other patient characteristics can complicate the interpretation of treatment response.

FDA's rare disease gene therapy guidance addresses these challenges. For conditions caused by genetic defects, it recommends testing all clinical trial subjects for the relevant genetic defect. It also emphasizes understanding disease progression, using natural history data where appropriate, and collecting as much pertinent information as possible from every participant.

These recommendations complement the manufacturing-focused potency guidance. Potency assurance establishes whether a product meets appropriate quality and biological activity standards; patient characterization provides context for understanding clinical outcomes.

For example, when patients respond differently to a therapy, sponsors need sufficient information to investigate whether those differences reflect disease characteristics, treatment-related factors, or other sources of variability.

Genetic confirmation, appropriate screening, and longitudinal data collection can all strengthen this clinical evidence base.

The new potency guidance does not establish these activities as potency requirements. Their relevance is to the broader challenge of generating interpretable evidence when trial populations are small.

We explored a related issue in our analysis of FDA's genome editing guidance, which examined why patient identification should be considered earlier in development.

How antibody screening can influence trial feasibility

Pre-existing antibodies offer a practical example of how patient characteristics can affect gene therapy trial planning.

For therapies using adeno-associated virus (AAV) vectors, pre-existing neutralizing antibodies can interfere with vector delivery, potentially limiting therapeutic activity or raising safety concerns.

FDA's rare disease gene therapy guidance acknowledges these risks. Where sponsors exclude patients based on antibody status, the agency recommends strongly considering parallel development of a companion diagnostic.

The proportion of patients with pre-existing antibodies varies substantially by AAV serotype, geography, and testing method.

A 2025 study published in Gene Therapy notes that pre-existing neutralizing antibodies to AAV capsids have been reported in approximately 40% to 70% of people. A separate 2026 multi-province study in China reported prevalence ranging from under 10% to over 90%, depending on serotype and region.

Assay selection can also affect eligibility. The 2025 Gene Therapy study found that one assay format classified up to 21.7% of samples as neutralizing that a conventional format had classified as non-neutralizing.

For programs where antibody status determines eligibility, differences between screening methods can affect the available patient population and the number of individuals who must be screened to meet enrollment targets.

Understanding these factors early can help sponsors develop more realistic feasibility assessments, anticipate screen failures, and plan recruitment strategies around the patients most likely to qualify.

Maintaining clinical evidence over time

The need for reliable clinical evidence does not end when enrollment is complete.

For rare disease gene therapy programs, long-term follow-up (LTFU) can extend years beyond initial treatment, making sustained patient engagement and consistent data collection important.

FDA's 2020 guidance on long-term follow-up after administration of human gene therapy products recommends risk-based monitoring periods that vary by product type. These may extend up to five years for AAV vectors and up to 15 years for integrating vectors and certain genome editing products.

The primary purpose of LTFU is to monitor for delayed adverse events, although sponsors may also assess treatment durability. FDA recommends making every effort to minimize loss to follow-up, and monitoring may continue after licensure.

Maintaining participant engagement over these periods can be difficult. Changes in healthcare providers, patient circumstances, and contact information can disrupt follow-up and leave gaps in clinical data.

As discussed in our article on the barriers to long-term follow-up in cell and gene therapy, addressing these challenges requires operational planning well beyond the initial recruitment period.

For small rare disease cohorts, retaining participants and collecting consistent longitudinal data are particularly valuable because opportunities to replace missing observations may be limited.

What CGT developers should consider next

FDA will host a webinar on December 10, 2026 to discuss the final potency assurance guidance.

For rare disease gene therapy developers, the immediate priority is understanding how potency testing and manufacturing controls established during development will support pivotal studies and eventual commercial specifications.

That planning should sit alongside equally deliberate clinical evidence strategies. Identifying genetically confirmed patients, understanding screening-related eligibility barriers, and maintaining long-term engagement can help sponsors build better-characterized cohorts and more complete outcome data.

The central lesson is that manufacturing readiness and clinical evidence generation require coordinated planning, particularly when every manufacturing lot and trial participant matters.

The new guidance provides greater clarity on FDA's expectations for potency assurance. For rare disease developers, applying that clarity alongside thoughtful clinical trial planning can help identify evidence gaps earlier and support the path from development to approval.

Get in touch